Estrogen- and antiestrogen-responsiveness of HEC1A endometrial adenocarcinoma cells in culture

Journal of Steroid Biochemistry and Molecular Biology

Volumn 64, Issue 5-6, 1998, Pages 287-295

  Castro Rivera, E ^a   Safe, S ^a  

^a TEXAS A AND M UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIESTROGEN; CATHEPSIN D; COMPLEMENT COMPONENT C3; CREATINE KINASE; ESTRADIOL; ESTROGEN RECEPTOR; FULVESTRANT; TAMOXIFEN;

ARTICLE; BIOLOGICAL MODEL; CELL CULTURE; CELL LINE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; ENDOMETRIUM CANCER; ENDOMETRIUM CARCINOMA; ENDOMETRIUM CELL; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; PROMOTER REGION; REPORTER GENE; TRANSACTIVATION;

CELL DIVISION; CHLORAMPHENICOL O-ACETYLTRANSFERASE; ENDOMETRIUM; ESTRADIOL; ESTROGEN ANTAGONISTS; ESTROGENS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, REPORTER; HUMANS; LUCIFERASES; NUCLEAR PROTEINS; RECEPTORS, ESTROGEN; TAMOXIFEN; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 0031922471     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-0760(97)00202-1     Document Type: Article

References (57)

1. Parazzini F., La Vecchia C., Bocciolone L., Franceschi S. The epidemiology of endometrial cancer. Gynecol. Oncol. 41:1991;1-16.
2. Fries L. A. G. Stat bite. Top 5 cancers for females and males in the U.S. J. Natl. Cancer Inst. 87:1995;867.
3. Silverberg E., Boring C. C., Squires T. S. Cancer statistics, 1990. CA. Cancer J. Clin. 40:1990;9-26.
4. Olson S. H., Trevisan M., Marshall J. R., Graham S., Zielezny M., Vena J. E., Hellmann R., Freudenheim J. L. Body mass index, weight gain, and risk of endometrial cancer. Nutr. Cancer. 23:1995;141-149.
5. Kvale G., Heuch I., Ursin G. Reproductive factors and risk of cancer of the uterine corpus: A prospective study. Cancer Res. 48:1988;6217-6221.
6. Smith D. C., Prentice R., Thompson D. J., Herrmann W. L. Association of exogenous estrogen and endometrial carcinoma. N. Engl. J. Med. 293:1975;1164-1167.
7. Anonymous Combination oral contraceptive use and the risk of endometrial cancer. The Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Human Development. JAMA. 257:1987;796-800.
8. Parazzini F., La Vecchia C., Negri E., Fedele L., Balotta F. Reproductive factors and risk of endometrial cancer. Am. J. Obstet. Gynecol. 164:1991;522-527.
9. Hulka B. S., Fowler W. C. Jr., Kaufman D. G., Grimson R. C., Greenberg B. G., Hogue C. J., Berger G. S., Pulliam C. C. Estrogen and endometrial cancer: Cases and two control groups from North Carolina. Am. J. Obstet. Gynecol. 137:1980;92-101.
10. Henderson B. E., Ross R., Bernstein L. Estrogens as a cause of human cancer: The Richard and Hinda Rosenthal Foundation award lecture. Cancer Res. 48:1988;246-253.
11. Key T. J. A., Pike M. C. The dose-effect relationship between 'unopposed' estrogens and endometrial mitotic rate: Its central role in explaining and predicting endometrial cancer risk. Br. J. Cancer. 57:1988;205-212.
12. Kedar R. P., Bourne T. H., Powles T. J., Collins W. P., Ashley S. E., Cosgrove D. O., Campbell S. Effects of tamoxifen on uterus and ovaries of postmenopausal women in a randomised breast cancer prevention trial. Lancet. 343:1994;1318-1321.
13. Fisher B., Costantino J. P., Redmond C. K., Fisher E. R., Wickerham D. L., Cronin W. M. Endometrial cancer in tamoxifen-treated breast cancer patients: Findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J. Natl. Cancer Inst. 86:1994;527-537.
14. Van Leeuwen F. E., Benraadt J., Coebergh J. W., Kiemeney L. A., Gimbrere C. H., Otter R., Schouten L. J., Damhuis R. A., Bontenbal M., Diepenhorst F. W. Risk of endometrial cancer after tamoxifen treatment of breast cancer. Lancet. 343:1994;448-452.
15. Curtis R. E., Boice J. D. Jr., Shriner D. A., Hankey B. F., Fraumeni J. F. Jr. Second cancers after adjuvant tamoxifen therapy for breast cancer. J. Natl. Cancer Inst. 88:1996;832-834.
16. Cook L. S., Weiss N. S., Schwartz S. M., White E., McKnight B., Moore D. E., Daling J. R. Population-based study of tamoxifen therapy and subsequent ovarian, endometrial, and breast cancers. J. Natl. Cancer Inst. 87:1995;1359-1364.
17. Horwitz K. B. When tamoxifen turns bad. Endocrinology. 136:1995;821-823.
18. Jordan V. C., Morrow M. Should clinicians be concerned about the carcinogenic potential of tamoxifen? Eur. J. Cancer. 30A:1994;1714-1721.
19. King C. M. Tamoxifen and the induction of cancer. Carcinogenesis. 16:1995;1449-1454.
20. Jordan V. C. Tamoxifen and tumorigenicity: A predictable concern. J. Natl. Cancer Inst. 87:1995;623-625.
21. Kuramoto H., Tamura S., Notake Y. Establishment of a cell line of human endometrial adenocarcinoma in vitro. Am. J. Obstet. Gynecol. 114:1972;1012-1019.
22. Holinka C. F., Hata H., Kuramoto H., Gurpide E. Effects of steroid hormones and antisteroids on alkaline phosphatase activity in human endometrial cancer cells (Ishikawa line). Cancer Res. 46:1986;2771-2774.
23. Holinka C. F., Hata H., Kuramoto H. Responses to estradiol in a human endometrial adenocarcinoma cell line (Ishikawa). J. Steroid Biochem. 24:1986;85-89.
24. Holinka C. F., Hata H., Gravanis A., Kuramoto H., Gurpide E. Effects of estradiol on proliferation of endometrial adenocarcinoma cells (Ishikawa line). J. Steroid Biochem. 25:1986;781-786.
25. Terakawa N., Hayashida M., Shimizu I., Ikegami H., Wakimoto H., Aono T., Tanizawa O., Matsumoto K., Nishida M. Growth inhibition by progestins in a human endometrial cancer cell line with estrogen-independent progesterone receptors. Cancer Res. 47:1987;1918-1923.
26. Holinka C. F., Anzai Y., Hata H., Kimmel N., Kuramoto H., Gurpide E. Proliferation and responsiveness to estrogen of human endometrial cancer cells under serum-free culture conditions. Cancer Res. 49:1989;3297-3301.
27. Anzai Y., Holinka C. F., Kuramoto H., Gurpide E. Stimulatory effects of 4-hydroxytamoxifen on proliferation of human endometrial adenocarcinoma cells (Ishikawa line). Cancer Res. 49:1989;2362-2365.
28. Jamil A., Croxtall J. D., White J. O. The effect of anti-estrogens on cell growth and progesterone receptor concentration in human endometrial cancer cells (Ishikawa). J. Mol. Endocrinol. 6:1991;215-221.
29. Miralles F., Gaudelet C., Cavailles V., Rochefort H., Augereau P. Insensitivity of cathepsin D gene to estradiol in endometrial cells is determined by the sequence of its estrogen responsive element. Biochem. Biophys. Res. Commun. 203:1994;711-718.
30. Touitou I., Cavailles V., Garcia M., DeFrenne A., Rochefort H. Differential regulation of cathepsin D by sex steroids in mammary cancer and uterine cells. Mol. Cell Endocrinol. 66:1989;231-238.
31. Morisset M., Capony F., Rochefort H. Processing and estrogen regulation of the 52 kDa protein inside MCF-7 breast cancer cells. Endocrinology. 119:1986;2773-2782.
32. May F. E. B., Westley B. R. Effects of tamoxifen and 4-hydroxytamoxifen on the pNR-1 and pNR-2 estrogen regulated RNAs in human breast cancer cells. J. Biol. Chem. 262:1987;15894-15899.
33. Westley B. R., May F. E. B. Estrogen regulates cathepsin D mRNA levels in estrogen responsive human breast cancer cells. Nucleic Acids Res. 15:1987;3773-3780.
34. Cavailles V., Augereau P., Garcia M., Rochefort H. Estrogens and growth factors induce mRNA of the 52K-pro-cathepsin-D secreted by breast cancer cells. Nucleic Acids Res. 16:1988;1903-1919.
35. Krishnan V., Narasimhan T. R., Safe S. Development of gel staining techniques for detecting the secretion of procathepsin D (52 kDa protein) in MCF-7 human breast cancer cells. Anal. Biochem. 204:1992;137-142.
36. Krishnan V., Porter W., Santostefano M., Wang X., Safe S. Molecular mechanism of inhibition of estrogen-induced cathepsin D gene expression by 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) in MCF-7 cells. Mol. Cell. Biol. 15:1995;6710-6719.
37. Nodland K. I., Wormke M., Safe S. Inhibition of estrogen-induced activity by 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) in the MCF-7 human breast cancer and other cell lines transfected with vitellogenin A2 gene promoter constructs. Arch. Biochem. Biophys. 338:1997;67-72.
38. Safe S. Modulation of gene expression and endocrine response pathways by 2,3,7,8-tetrachlorodibenzo-p-dioxin and related compounds. Pharmacol. Ther. 67:1995;247-281.
39. Hobson G. M., Molloy G. R., Benfield P. A. Identification of cis-acting regulatory elements in the promoter region of the rat brain creatine kinase gene. Mol. Cell. Biol. 10:1990;6533-6543.
40. Sundstrom S. A., Komm B. S., Xu Q., Boundy V., Lyttle C. R. The stimulation of uterine complement component C3 gene expression by antiestrogens. Endocrinology. 126:1990;1449-1456.
41. Tzukerman M. T., Esty A., Santiso-Mere D., Danielian P., Parker M. G., Stein R. G., Pike J. W., McDonnell D. P. Human estrogen receptor transactivational capacity is determined by both cellular and promoter context and mediated by two functionally distinct intramolecular regions. Mol. Endocrinol. 8:1994;21-30.
42. McDonnell D. P., Clemm D. L., Hermann T., Goldman M. E., Pike J. W. Analysis of estrogen receptor function in vitro reveals three distinct classes of antiestrogens. Mol. Endocrinol. 9:1995;659-669.
43. Norris J. D., Fan D. J., Wagner B. L., McDonnell D. P. Identification of the sequences within the human complement 3 promoter required for estrogen responsiveness provides insight into the mechanism of tamoxifen mixed agonist activity. Mol. Endocrinol. 10:1996;1605-1616.
44. Dickson R. B., Lippman M. E. Estrogenic regulation of growth and polypeptide growth factor secretion in human breast carcinoma. Endocrine Rev. 8:1987;29-43.
45. Dickson R. B., Lippman M. E. Hormonal control of human breast cancer cell lines. Cancer Surveys. 5:1986;617-624.
46. Lippman M. E., Dickson R. B. Mechanisms of growth control in normal and malignant breast epithelium. Recent Prog. Hormone Res. 45:1989;383-440.
47. Hana V., Murphy L. J. Expression of insulin-like growth factors and their binding proteins in the estrogen responsive Ishikawa human endometrial cancer cell line. Endocrinology. 135:1994;2511-2516.
48. Gong Y., Ballejo G., Murphy L. C., Murphy L. J. Differential effects of estrogen and antiestrogen on transforming growth factor gene expression in endometrial adenocarcinoma cells. Cancer Res. 52:1992;1704-1709.
49. Safe S. MCDF, 6-methyl-1,3,8-trichlorodibenzofuran. Drugs Future. 17:1992;564-565.
50. Fujimoto J., Hori M., Ichigo S., Morishita S., Tamaya T. Estrogen activates migration potential of endometrial cancer cells through basement membrane. Tumour. Biol. 17:1996;48-57.
51. Nguyen H. N., Sevin B. U., Averette H. E., Voigt W., Perras J., Angioli R., Ramos R., Donato D., Penalver M. Determination of hormonal response in uterine cancer cell lines by the ATP bioluminescence assay and flow cytometry. Gynecol. Oncol. 46:1992;55-61.
52. Jordan V. C. Biochemical pharmacology of antiestrogen action. Pharmacol. Rev. 36:1984;245-270.
53. Ramamoorthy K., Wang F., Chen I.-C., Norris J. D., McDonnell D. P., Gaido K. W., Bocchinfuso W. P., Korach K. S., Safe S. Estrogenic activity of a dieldrin/toxaphene mixture in the mouse uterus, MCF-7 human breast cancer cells and yeast-based estrogen receptor assays: No apparent synergism. Endocrinology. 138:1997;1520-1527.
54. Kuiper G. G., Enmark E., Pelto-Huikko M., Nilsson S., Gustafsson J. A. Cloning of a novel receptor expressed in rat prostate and ovary. Proc. Natl. Acad. Sci. USA. 93:1996;5925-5930.
55. Kuiper G. G., Carlsson B., Grandien K., Enmark E., Häggblad J., Nilsson S., Gustafsson J. A. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors α and β Endocrinology. 138:1997;863-870.
56. Watanabe T., Inoue S., Ogawa S., Ishii Y., Hiroi H., Ikeda K., Orimo A., Muramatsu M. Agonistic effect of tamoxifen is dependent on cell type, ERE-promoter context, and estrogen receptor subtype: Functional difference between estrogen receptors α and β Biochem. Biophys. Res. Commun. 236:1997;140-145.
57. Katzenellenbogen J. A., O'Malley B. W., Katzenellenbogen B. S. Tripartite steroid hormone receptor pharmacology: Interaction with multiple effector sites as a basis for the cell- and promoter-specific action of these hormones. Mol. Endocrinol. 10:1996;119-131.